Aav

Pic:getty/sewcream

Rocket Pharmaceuticals to acquire Renovacor

By Rachel Arthur

Rocket Pharmaceuticals, a late-stage, clinical biotech advancing a pipeline of genetic therapies for rare childhood disorders, will acquire Renovacor: helping it strengthen its position in AAV-based cardiac gene therapy.

© GettyImages/BlackJack3D

AskBio and Touchlight restructure JV targeting AAV market

By Jane Byrne

AskBio, a gene therapy company owned and operated as a subsidiary of Bayer AG, and Touchlight, a biotech focused on enzymatic DNA production, have announced a revised structure to their former joint venture, Touchlight AAV.

© GettyImages/AlexanderFord

Ocular gene therapy biotech launches with $19M seed funding

By Jane Byrne

This month sees the launch of a new gene therapy player, Opus Genetics, a company backed and spun out by leading patient group Foundation Fighting Blindness’ venture arm, the Retinal Degeneration Fund (RD Fund).

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers